Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

12 Mar
Orange Guide logo
Orange Guide March 2019 Update

Updates have been made to the Code of Practice for Qualified Persons in chapter three, Guidance on Manufacture and Importation.

12 Mar
Palliative Care Formulary March 2019 Update

This update contains 3 revised monographs.

Pancreatin and Prolongation of the QT interval in palliative care have been fully revised. Levetiracetam has undergone minor revision.

 

12 Mar
Martindale logo
Martindale March 2019 Update

This update contains 13 new monographs and 22 existing monographs have been updated. Preparations have been updated for 5 countries.

New monographs: 

  • Baloxavir Marboxil: baloxavir is a polymerase acidic endonuclease inhibitor with antiviral activity. It is used as the marboxil salt to treat acute uncomplicated influenza A and B.
  • Binimetinib: an inhibitor of mitogen-activated extracellular kinase (MEK 1 and 2) that is used, with encorafenib, for the treatment of unresectable or metastatic melanoma.
  • Doravirine: is a non-nucleoside reverse transcriptase inhibitor, used with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-naïve patients.
  • Encorafenib: is a BRAF kinase inhibitor that is used, with binimetinib, for unresectable or metastatic melanoma.
  • Fostamatinib: is a spleen tyrosine kinase inhibitor. It is used for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia who have had an inadequate response to other therapies.
  • Fremanezumab: is a calcitonin gene-related peptide antagonist that is used for the prevention of migraine.
  • Galcanezumab: is a calcitonin gene-related peptide antagonist that is used for the prevention of migraine.
  • Ivosidenib: is an isocitrate dehydrogenase-1 (IDH1) inhibitor used in the treatment of relapsed or refractory acute myeloid leukaemia with an IDH1 mutation.
  • Lanadelumab: is a monoclonal antibody that inhibits plasma kallikrein. It is used as prophylaxis to prevent hereditary angioedema attacks.
  • Omadacycline: is an aminomethylcycline antibacterial that is used for the treatment of community-acquired pneumonia and acute skin and skin structure infections.
  • Ravulizumab: is a C5 complement blocker that is used for the treatment of paroxysmal nocturnal haemoglobinuria.
  • Revefenacin: is a long-acting antimuscarinic that is used via inhalation in the treatment of chronic obstructive pulmonary disease.
  • Vonicog Alfa: is a recombinant von Willebrand factor that is used for the treatment and prevention of bleeding in patients with von Willebrand’s disease.

Notable revisions: 

  • Cabozantinib: is used for the treatment of hepatocellular carcinoma and as a first-line option for renal cell carcinoma.
  • Chloroquine: updated guidance on screening for retinopathy, and caution regarding lowering of the seizure threshold.
  • Crisaborole: is a phosphodiesterase type-4 (PDE-4) inhibitor that is used for the topical treatment of mild to moderate atopic eczema.
  • Denosumab: can be used for bone loss following long-term glucocorticoid therapy and for the prevention of skeletal events associated with multiple myeloma.
  • Durvalumab: is used for non-small cell lung cancer in adults whose tumours express PD-L1 and whose disease has not progressed following platinum-based chemotherapy and radiation therapy.
  • Eslicarbazepine: can be used in children for the treatment of partial seizures, either as monotherapy or adjuvant therapy.
  • Hydroxychloroquine: updated dosing, guidance on screening for retinopathy, and caution regarding lowering of the seizure threshold.
  • Ipilimumab:  is used for the treatment of melanoma, renal cell carcinoma, and microsatellite instability-high or mismatch repair deficient colorectal cancer.  Immune-mediated adverse effects, including fatalities, have been reported.
  • Nivolumab: is used for the treatment of squamous cell carcinoma of the head and neck, advanced urothelial carcinoma, hepatocellular carcinoma, and metastatic colorectal cancer. Immune-mediated adverse effects, including fatalities, have been reported.
  • Pembrolizumab: is used for the treatment of classical Hodgkin’s lymphoma, urothelial carcinoma, B-cell lymphoma, gastric or gastro-oesophageal junction adenocarcinoma, and microsatellite instability-high or mismatch repair deficient solid tumours or colorectal cancer, and cervical cancer.  Immune-mediated adverse effects, including fatalities, have been reported.
  • Pivmecillinam: updated dosing for acute uncomplicated cystitis in adults and treatment of urinary tract infections in children.
  • Tolvaptan: updated dosing when patient is at risk of too rapid correction of sodium. Precautions on liver function test monitoring, interactions with CYP3A4, and side effects also updated.
  • Valganciclovir Hydrochloride: can be used in children for CMV prophylaxis in those who have had a transplant from a CMV-positive donor.

Updated names, synonyms and codes; official standards; official preparations:

  • BP 2018
  • Ph Eur 9.4 and 9.5

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • BP 2018
  • Denmark
  • Finland
  • Netherlands
  • UK†
  • USA†

† Countries updated on an ongoing basis

12 Mar
AHFS Drug Information logo
AHFS March 2019 Update

This update contains 4 new monographs, 35 revised monographs, 9 discontinued monographs and 6 new MedWatch alerts.

New monographs: Prucalopride; Ravulizumab-cwvz; Amifampridine; Tagraxofusp-erzs

Revised monographs: Moxifloxacin; Cevimeline; Gemifloxacin; Ambrisentan; Nebivolol; Liraglutide; Pitavastatin; Azilsartan; Canagliflozin; Riociguat; Sofosbuvir; Dapagliflozin; Pembrolizumab; Empagliflozin; Atezolizumab; Delafloxacin; Copanlisib; Pilocarpine; Magnesium Sulfate; Chlorthalidone; metOLazone; Methyclothiazide; hydroCHLOROthiazide; Bendroflumethiazide; Nadolol; Nystatin; Calcium Salts; Indapamide; Ciprofloxacin; ASHP Guidelines on Handling Hazardous Drugs; Ofloxacin; Fosfomycin; Azithromycin; levoFLOXacin; tiaGABine Hydrochloride 

Discontinued monographs: Telithromycin; telbivudine; albiglutide; dasabuvir, ombitasvir, paritaprevir, and ritonavir; ombitasvir, paritaprevir, and ritonavir; erythromycin estolate; insulin zinc; nystatin; ticarcillin and clavulanate 

New MedWatch alerts on the following monographs: moxifloxacin; gemifloxacin; delafloxacin; ciprofloxacin; ofloxacin; levofloxacin

12 Mar
British National Formulary for Children logo
BNFC March 2019 update

This update contains 8 significant changes, 4 dose changes and 1 new preparation. 

Significant Changes:  

  • Anthrax vaccine: updated guidance in-line with Public Health England recommendations.
  • Attention deficit hyperactivity disorder: updated guidance on management.
  • Cholera vaccine: updated guidance in-line with Public Health England recommendations.
  • Ipilimumab (Yervoy®): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation [MHRA/CHM advice].
  • Japanese encephalitis vaccine: updated guidance in-line with Public Health England recommendations.
  • Methotrexate: updated recommendations for conception and contraception.
  • Tapentadol(Palexia®): risk of seizures and reports of serotonin syndrome when co-administered with other medicines [MHRA/CHM advice]. 
  • Typhoid vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes: 

  • Adalimumab [maintenance dosing updated].
  • Anthrax vaccine [dosing schedule updated].
  • Imipenem with cilastatin[dosing recommendation in renal impairment updated]. 
  • Japanese encephalitis vaccine [dosing schedule updated].

New Preparations: Palexia® oral solution [tapentadol] 

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

12 Mar
British National Formulary logo
BNF March 2019 update

This update contains 16 significant changes, 5 dose changes and 3 new preparations.

Significant Changes:  

  • Anthrax vaccine: updated guidance in-line with Public Health England recommendations.
  • Attention deficit hyperactivity disorder: updated guidance on management.
  • Breast cancer: updated guidance on management.
  • Cholera vaccine: updated guidance in-line with Public Health England recommendations.
  • Chronic heart failure: updated guidance on management.
  • Heavy menstrual bleeding: updated recommendations for the use of ulipristal acetate.
  • Ipilimumab (Yervoy®): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation [MHRA/CHM advice].
  • Japanese encephalitis vaccine: updated guidance in-line with Public Health England recommendations.
  • Lenvatinib for untreated advanced hepatocellular carcinoma [NICE guidance].
  • Methotrexate: updated recommendations for conception and contraception.
  • Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease [NICE guidance].
  • Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence [NICE guidance].
  • Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer [NICE guidance].
  • Regorafenib for previously treated advanced hepatocellular carcinoma [NICE guidance].
  • Tapentadol (Palexia®): risk of seizures and reports of serotonin syndrome when co-administered with other medicines [MHRA/CHM advice].
  • Typhoid vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes:

  • Adalimumab [maintenance dosing updated].
  • Anthrax vaccine [dosing schedule updated].
  • Imipenem with cilastatin [dosing recommendation in renal impairment updated].
  • Japanese encephalitis vaccine [dosing schedule updated].
  • Pembrolizumab [dose for non-small cell lung cancer (following prior chemotherapy) and melanoma].

New Preparations: Alunbrig® [brigatinib], Ozempic® [semaglutide], Steglatro® [ertugliflozin].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

View more